{"description":"Adverse events were captured for patients who received DLI and AP1903.","eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":0,"description":"Patients who did not move forward to DLI","id":"EG000","otherNumAffected":0,"otherNumAtRisk":0,"seriousNumAffected":0,"seriousNumAtRisk":0,"title":"Transplant Only"},{"deathsNumAffected":1,"deathsNumAtRisk":1,"description":"Proceeded to DLI per protocol","id":"EG001","otherNumAffected":1,"otherNumAtRisk":1,"seriousNumAffected":1,"seriousNumAtRisk":1,"title":"Transplat Plus DLI"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":0},{"groupId":"EG001","numAffected":1,"numAtRisk":1}],"term":"Elevated creatinine"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":0},{"groupId":"EG001","numAffected":1,"numAtRisk":1}],"term":"Infection (CMV)"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":0},{"groupId":"EG001","numAffected":1,"numAtRisk":1}],"term":"Infection (adenovirus)"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":0},{"groupId":"EG001","numAffected":1,"numAtRisk":1}],"term":"Infection (E.Coli)"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":0},{"groupId":"EG001","numAffected":1,"numAtRisk":1}],"term":"Nausea"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":0},{"groupId":"EG001","numAffected":1,"numAtRisk":1}],"term":"Skin Rash"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (4.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":0},{"groupId":"EG001","numAffected":1,"numAtRisk":1}],"term":"Infection"}],"timeFrame":"up to 30 days after DLI or after AP1903 infusion, whichever is later"}